In the last trading session, 2,710,699 shares of the AcelRx Pharmaceuticals, Inc.(NASDAQ:ACRX) were traded, and its beta was 0.97. Most recently the company’s share price was $2.16, and it changed around $0 or 0% from the last close, which brings the market valuation of the company to $245.83 Million. ACRX currently trades at a discount to its 52-week high of $2.94, offering almost -36.11% off that amount. The share price’s 52-week low was $0.7, which indicates that the current value has risen by an impressive 67.59% since then. We note from AcelRx Pharmaceuticals, Inc.’s average daily trading volume that its 10-day average is 4.47 Million shares, with the 3-month average coming to 5.57 Million.
AcelRx Pharmaceuticals, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.2. If we narrow it down even further, the data shows that 1 out of 4 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended ACRX as a Hold, whereas 3 deemed it a Buy, and no one rated it as Underweight. AcelRx Pharmaceuticals, Inc. is expected to report earnings per share of -$0.1 for the current quarter.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Trading Information
Although ACRX has showed a red trend with a performance of 0% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $2.60- on Friday, Feb 12 increased the stock’s daily price by 16.92%. The company’s shares are currently up 0.74% year-to-date, but still down -0.1787 over the last five days. On the other hand, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is -0.08% down in the 30-day period. We can see from the shorts that 10.98 Million shares have been sold at a short interest cover period of 1.97 day(s).
The consensus price target as assigned by Wall Street analysts is $5.46, which translates to bears needing to increase their stock price by 152.78% from its current value. Analyst projections state that ACRX is forecast to be at a low of $0.83 and a high of $9. In order for the stock price to hit the forecast high, the stock would need to surge +316.67% from its current level, while the stock would need to crash -61.57% from its current level to reach the projected low.
AcelRx Pharmaceuticals, Inc. (ACRX) projections and forecasts
AcelRx Pharmaceuticals, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +52.11 percent over the past six months and at a 28.36% annual growth rate that is well above the industry average of 17.3%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +44.4% in revenue this quarter, and will report an increase of 60% in the next quarter. The year-over-year growth rate is expected to be 178.7%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $1.73 Million in revenue for the current quarter. 2 analysts expect AcelRx Pharmaceuticals, Inc. to make $2.3 Million in revenue for the quarter ending March 01, 2021. The company’s sales for the same quarters a year ago were $475Million and $386Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 264.2%. Forecasts for the next quarter put sales growth at 495.9%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 2.6%. AcelRx Pharmaceuticals, Inc. earnings are expected to increase by 16.7% in 2021, but the outlook is negative 0% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 2.11% of AcelRx Pharmaceuticals, Inc. shares, and 26.93% of them are in the hands of institutional investors. The stock currently has a share float of 27.51%. AcelRx Pharmaceuticals, Inc. stock is held by 100 institutions, with Blackrock Inc. being the largest institutional investor. By Dec 30, 2020, it held 6.23% of the shares, which is about 5.64 Million shares worth $6.99 Million.
Vanguard Group, Inc. (The), with 4.51% or 4.08 Million shares worth $5.8 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.